PL2640362T5 - Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru - Google Patents

Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru

Info

Publication number
PL2640362T5
PL2640362T5 PL11791161T PL11791161T PL2640362T5 PL 2640362 T5 PL2640362 T5 PL 2640362T5 PL 11791161 T PL11791161 T PL 11791161T PL 11791161 T PL11791161 T PL 11791161T PL 2640362 T5 PL2640362 T5 PL 2640362T5
Authority
PL
Poland
Prior art keywords
tenovofir
rilpivirin
hcl
therapeutic compositions
disoproxil fumarate
Prior art date
Application number
PL11791161T
Other languages
English (en)
Polish (pl)
Other versions
PL2640362T3 (pl
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences, Inc.
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2640362(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc., Janssen Sciences Ireland Uc filed Critical Gilead Sciences, Inc.
Publication of PL2640362T3 publication Critical patent/PL2640362T3/pl
Publication of PL2640362T5 publication Critical patent/PL2640362T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11791161T 2010-11-19 2011-11-18 Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru PL2640362T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
EP11791161.0A EP2640362B2 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Publications (2)

Publication Number Publication Date
PL2640362T3 PL2640362T3 (pl) 2015-03-31
PL2640362T5 true PL2640362T5 (pl) 2022-05-02

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11791161T PL2640362T5 (pl) 2010-11-19 2011-11-18 Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru

Country Status (36)

Country Link
US (1) US10857102B2 (enExample)
EP (2) EP2640362B2 (enExample)
JP (2) JP2014500261A (enExample)
KR (1) KR101923103B1 (enExample)
CN (2) CN106511357A (enExample)
AP (1) AP3816A (enExample)
AR (2) AR084500A1 (enExample)
AU (3) AU2011329642B2 (enExample)
BR (1) BR112013012245B1 (enExample)
CA (1) CA2818097C (enExample)
CL (1) CL2013001402A1 (enExample)
CO (1) CO6761300A2 (enExample)
CR (1) CR20130293A (enExample)
DK (1) DK2640362T4 (enExample)
EA (2) EA201691695A1 (enExample)
EC (2) ECSP13012700A (enExample)
ES (1) ES2524408T5 (enExample)
HK (1) HK1206592A1 (enExample)
HR (1) HRP20140946T1 (enExample)
IL (1) IL226300B (enExample)
MA (1) MA34735B1 (enExample)
ME (1) ME01980B (enExample)
MX (1) MX347512B (enExample)
MY (1) MY185604A (enExample)
NZ (1) NZ610729A (enExample)
PE (3) PE20211657A1 (enExample)
PH (1) PH12013501002A1 (enExample)
PL (1) PL2640362T5 (enExample)
PT (1) PT2640362E (enExample)
RS (1) RS53691B1 (enExample)
SG (3) SG190333A1 (enExample)
SM (1) SMT201400150B (enExample)
TW (1) TWI556840B (enExample)
UA (1) UA114075C2 (enExample)
WO (1) WO2012068535A1 (enExample)
ZA (1) ZA201304481B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AP3639A (en) 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1933815A2 (en) 2005-10-14 2008-06-25 Microdose Technologies Inc. Pharmaceutical packaging of an oral dosage combination
ATE474560T1 (de) 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PL2393485T3 (pl) 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Also Published As

Publication number Publication date
ES2524408T5 (es) 2022-04-25
PH12013501002A1 (en) 2013-09-09
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
CL2013001402A1 (es) 2013-12-27
TW201238612A (en) 2012-10-01
DK2640362T3 (en) 2014-12-01
AU2018202635A1 (en) 2018-05-10
HK1190064A1 (en) 2014-06-27
AP3816A (en) 2016-09-30
SMT201400150B (it) 2015-01-15
MX2013005669A (es) 2013-11-04
PL2640362T3 (pl) 2015-03-31
PE20140163A1 (es) 2014-02-08
SG190333A1 (en) 2013-06-28
EA025852B1 (ru) 2017-02-28
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
EA201691695A1 (ru) 2017-11-30
US10857102B2 (en) 2020-12-08
HK1206592A1 (en) 2016-01-15
EP2640362B1 (en) 2014-09-10
UA114075C2 (xx) 2017-04-25
KR101923103B1 (ko) 2018-11-28
AU2011329642A1 (en) 2013-05-02
RS53691B1 (sr) 2015-04-30
MA34735B1 (fr) 2013-12-03
US20130243857A1 (en) 2013-09-19
AU2016208417B2 (en) 2018-04-05
EA201390651A1 (ru) 2013-11-29
AR084500A1 (es) 2013-05-22
AP2013006931A0 (en) 2013-06-30
KR20140037799A (ko) 2014-03-27
PT2640362E (pt) 2014-11-28
MX347512B (es) 2017-04-28
ECSP13012700A (es) 2013-08-30
AR123409A2 (es) 2022-11-30
CO6761300A2 (es) 2013-09-30
SG10201912527XA (en) 2020-02-27
JP2014500261A (ja) 2014-01-09
PE20211657A1 (es) 2021-08-24
MY185604A (en) 2021-05-25
BR112013012245A2 (pt) 2016-08-09
IL226300B (en) 2019-05-30
TWI556840B (zh) 2016-11-11
ES2524408T3 (es) 2014-12-09
BR112013012245B1 (pt) 2022-09-27
EP2640362B2 (en) 2021-12-01
CA2818097C (en) 2019-07-30
CN103491948A (zh) 2014-01-01
CN103491948B (zh) 2016-11-02
ZA201304481B (en) 2022-03-30
NZ610729A (en) 2015-10-30
PE20170521A1 (es) 2017-05-27
EP2826466A1 (en) 2015-01-21
HRP20140946T1 (hr) 2015-02-13
CR20130293A (es) 2013-10-03
JP2015131853A (ja) 2015-07-23
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
SG10201509521WA (en) 2015-12-30
WO2012068535A1 (en) 2012-05-24
CA2818097A1 (en) 2012-05-24
AU2016208417A1 (en) 2016-08-18
EP2640362A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
PL2640362T3 (pl) Kompozycje terapeutyczne zawierające HCl rilpiwiryny i fumaran dizoproksylu tenofowiru
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
PL2510072T3 (pl) Terapeutyczne i kosmetyczne kompozycje elektroluminescencyjne
ZA201403372B (en) Therapeutic agents and uses thereof
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
IL230120B (en) Preparations containing recombinant iduronate-2-sulfatase and their uses
IL218212A0 (en) Therapeutic methods and compositions
EP2643000A4 (en) THERAPEUTIC PIPERAZINES
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
GB201005625D0 (en) Immunogenic proteins and compositions
HUE037850T2 (hu) Új amidszármazék és alkalmazása gyógyszerként
PL2521445T3 (pl) Preparat i jego zastosowanie
GB201011411D0 (en) Therapeutic compounds and their use
PT2563806E (pt) Leucolectinas humanas e suas utilizações
SG10201602111VA (en) Formulations Comprising Methylthioninium Chloride
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
SI2640362T1 (sl) Terapevtski sestavki, ki vsebujejo rilpivirin hcl in tenovofir disoproksil
ZA201209021B (en) Therapeutic peptide composition and method
GB201003741D0 (en) Methods and therapeutic compositions
AU332227S (en) Therapeutic pillow
GB201006380D0 (en) Excipients and their use
GB201016149D0 (en) Effective and essential bedding and table clothing
GB201012660D0 (en) Inhaler and formulation
GB201010582D0 (en) Therapeutic agents